People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OrderMark, Inc. | — | Other Technology | Series D+ | $139.3M | $3.2B | 2018 |
| Ray Therapeutics, Inc. | — | Biotechnology | Series A | $20.0M | $126.9M | 2021 |
Gary Abrams at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gary Abrams on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Cohn | 1 | 10 |
| Chris Moody | 1 | 9 |
| Tiba Aynechi | 1 | 9 |
| Paul Allen | 1 | 8 |
| Sean Ainsworth | 1 | 5 |
| MICHAEL JACOBS | 1 | 4 |
| Andrew Howard | 1 | 4 |
| Raymond Camahort | 1 | 4 |
| Dmitry Kuzmin | 1 | 3 |
| Jeffrey Housenbold | 1 | 3 |
| Ian Loizeaux | 1 | 3 |
| Paul Bresge | 1 | 2 |
| Hannah Chang | 1 | 2 |
| Alex Canter | 1 | 1 |
| Cameron Gallagher | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.